Evidence map›Paper›PMID 37847906›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

Distinct Conformations of Mirabegron Determined by MicroED.

Jieye Lin, Johan Unge, Tamir Gonen

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Unraveling atomic complexity from frozen samples.Structural dynamics (Melville, N.Y.) · 2025
    Article
  4. Applying 3D ED/MicroED workflows toward the next frontiers.Acta crystallographica. Section C, Structural chemistry · 2024
    Article
  5. Article
  6. Article
  7. Distinct Conformations of Mirabegron Determined by MicroED.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jieye LinDepartment of Biological Chemistry, University of California, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Johan UngeDepartment of Biological Chemistry, University of California, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Tamir GonenDepartment of Biological Chemistry, University of California, 615 Charles E. Young Drive South, Los Angeles, CA, 90095, USA.
Charles R. Drew University of Medicine and Science · USUniversity of California, Los Angeles · US

Funding

TRD4: Design and Engineering of MicroED hardware for nanocrystallization and time resolved studiesP41GM136508 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GONEN, TAMIR · 2020 to 2024
$7.6M
Howard Hughes Medical InstituteNIGMS NIH HHS P41 GM136508NIH HHS P41GM136508
6 · The paper itself

Abstract

Mirabegron, commonly known as "Myrbetriq", has been widely prescribed as a medicine for overactive bladder syndrome for over a decade. However, the structure of the drug and what conformational changes it may undergo upon binding its receptor remain unknown. In this study, the authors employed microcrystal electron diffraction (MicroED) to reveal its elusive three-dimensional (3D) structure. They find that the drug adopts two distinct conformational states (conformers) within the asymmetric unit. Analysis of hydrogen bonding and packing demonstrated that the hydrophilic groups are embedded within the crystal lattice, resulting in a hydrophobic surface and low water solubility. Structural comparison revealed the presence of trans- and cis- forms in conformers 1 and 2, respectively. Comparison of the structures of Mirabegron alone with that of the drug bound to its receptor, the beta 3 adrenergic receptor (β3AR) suggests that the drug undergoes major conformational change to fit in the receptor agonist binding site. This research highlights the efficacy of MicroED in determining the unknown and polymorphic structures of active pharmaceutical ingredients (APIs) directly from powders.

Indexed as

Urinary Bladder, OveractiveAcetanilidesAdrenergic beta-3 Receptor AgonistsElectronsHumansThiazolesAcetanilidesAdrenergic beta-3 Receptor AgonistsmirabegronThiazolesactive pharmaceutical ingredientconformercrystallographymicrocrystal electron diffraction (microed)mirabegron

Identifiers

PMID37847906
PMCPMC10700164
OpenAlexW4387698864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.